105
In the publication that has just appeared, the team of authors around Dr. John R. Sims, an Eli Lilly collaborator, on the occurrence of ARIA: ARIA-E occurred in 205 of 853 donanemab-treated patients (24.0 percent) in the 18-month study and in 18 of 874 in the placebo group patients (2.1 percent). 52 of the affected patients with ARIA-E under donanemab, but none from the placebo group, showed symptoms such as headaches or increased confusion, but in some cases also seizures. ARIA-H were also more frequent under donanemab with 268 affected persons (31.4 percent) than under placebo (119 affected persons or 13.6 percent).